KLOX Technologies launches two studies for chronic wound healing using biophotonic technology

KLOX Technologies (Montreal, QC, Canada) is launching two simultaneous investigational studies of the company's Biophotonic System for chronic wound healing, respectively. Slated to begin this month (January 2013), the two studies for treating chronic venous leg and pressure ulcers, respectively, using the system follow receipt of Investigational Testing Authorizations from Health Canada for a Class II medical device.

Both the venous leg ulcer and pressure ulcer studies that are being rolled out in Canada are multi-center, open-label, non-controlled, prospective case series of a 26-week maximum duration. Their objectives are to validate the safety and tolerability of the treatment, as well as to gather preliminary efficacy data. The goal is to recruit and treat adult patients through a maximum of three investigational sites located in Canada for each study, the first of which will be launched in Montreal.

In December 2012, the company filed a request for a Pre-Market Authorization (PMA) process in the U.S. to initiate a trial to assess the system in pressure sores, and expects a response from the FDA in the coming weeks. The company will continue to seek approval from Canadian, European and U.S. regulatory authorities to conduct another series of studies that will include the system for treating diabetic foot ulcers and Stage III pressure ulcers.

In Europe, the company has completed a registration trial with its system for treating moderate to severe acne. Top-line data will be available soon.

-----

Follow us on Twitter, 'like' us on Facebook, and join our group on LinkedIn

Subscribe now to BioOptics World magazine; it's free!

Get All the BioOptics World News Delivered to Your Inbox

Subscribe to BioOptics World Magazine or email newsletter today at no cost and receive the latest news and information.

 Subscribe Now
Related Articles

Clinical trial for multibeam OCT system yields positive top line results

Michelson Diagnostics recently completed a multicenter, prospective clinical trial for basal cell carcinoma diagnosis using the company's VivoSight multibeam optical coherence tomography (OCT) syst...

Michelson Diagnostics finalizes data collection in OCT trial for basal cell carcinoma diagnosis

Michelson Diagnostics, which specializes in multibeam optical coherence tomography (OCT) technology, has completed scanning and data collection for a 250-patient, multicenter clinical trial testing...

CCNY physicists patent optical method to change skin-color perception

In August 2013, three City College of New York (CCNY) physicists affiliated with the Institute for Ultrafast Spectroscopy and Lasers (IUSL) were awarded a patent for a method for changing perceptio...

Ablative CO2 laser effective for rhinophyma

Good cosmetic outcomes are possible using fractionated ablative carbon dioxide (CO2) laser therapy for mild-to-moderate cases of rhinophyma, according to researchers at the University of California...

BLOGS

Neuro15 exhibitors meet exacting demands: Part 2

Increasingly, neuroscientists are working with researchers in disciplines such as chemistry and p...

Why be free?

A successful career contributed to keeping OpticalRayTracer—an optical design software program—fr...

LASER Munich 2015 is bio-bent

LASER World of Photonics 2015 included the European Conferences on Biomedical Optics among its si...

White Papers

Understanding Optical Filters

Optical filters can be used to attenuate or enhance an image, transmit or reflect specific wavele...

How can I find the right digital camera for my microscopy application?

Nowadays, image processing is found in a wide range of optical microscopy applications. Examples ...

CONNECT WITH US

            

Twitter- BioOptics World

Copyright © 2007-2016. PennWell Corporation, Tulsa, OK. All Rights Reserved.PRIVACY POLICY | TERMS AND CONDITIONS